CDKN1B and systemic lupus erythematosus: Sui et al. reported that cyclin-dependent kinase inhibitor 1B (CDKN1B) exhibited significantly decreased levels of 5-hmC in the PBMCs of SLE patients, whereas three prime repair exonuclease (TREX1) and CDKN1A showed increased levels of 5-hmC [47].